FY2025 EPS Estimates for CervoMed Boosted by Chardan Capital

CervoMed Inc. (NASDAQ:CRVO) – Research analysts at Chardan Capital boosted their FY2025 earnings per share estimates for shares of CervoMed in a report released on Monday, August 11th. Chardan Capital analyst D. Gataulin now anticipates that the company will post earnings of ($2.56) per share for the year, up from their previous forecast of ($2.57). Chardan Capital currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Chardan Capital also issued estimates for CervoMed’s FY2026 earnings at ($1.15) EPS.

Several other research analysts have also recently weighed in on the company. Canaccord Genuity Group boosted their target price on CervoMed from $21.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, July 29th. Roth Capital set a $16.00 target price on CervoMed and gave the stock a “buy” rating in a report on Tuesday. Finally, D. Boral Capital boosted their target price on CervoMed from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $21.43.

CervoMed Price Performance

Shares of CervoMed stock opened at $10.19 on Thursday. The stock has a market cap of $94.26 million, a P/E ratio of -3.90 and a beta of -0.79. The stock’s 50 day simple moving average is $7.69 and its 200-day simple moving average is $7.11. CervoMed has a 1-year low of $1.80 and a 1-year high of $20.63.

CervoMed (NASDAQ:CRVO) last issued its earnings results on Friday, August 8th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.13). The company had revenue of $1.76 million for the quarter, compared to analyst estimates of $1.45 million. CervoMed had a negative return on equity of 59.15% and a negative net margin of 290.72%.

Institutional Trading of CervoMed

Institutional investors have recently made changes to their positions in the company. Mariner LLC purchased a new stake in shares of CervoMed during the 4th quarter valued at approximately $30,000. BNP Paribas Financial Markets purchased a new stake in shares of CervoMed during the 4th quarter valued at approximately $32,000. JPMorgan Chase & Co. raised its position in CervoMed by 251.8% in the fourth quarter. JPMorgan Chase & Co. now owns 14,464 shares of the company’s stock valued at $34,000 after purchasing an additional 10,352 shares during the period. Rhumbline Advisers raised its position in CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after purchasing an additional 1,526 shares during the period. Finally, Marshall Wace LLP purchased a new stake in CervoMed in the second quarter valued at approximately $76,000. Hedge funds and other institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.